Clinical Trials · NCT00833716
Effect of Renal Impairment on the Pharmacokinetics of NN9535
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 62
- Start date
- Feb 2009
- Locations
- 3 sites, United States
- Primary endpoint
- AUC of NN9535